Table 2 Baseline characteristics of selected trials of EGDT in severe sepsis or septic shock
Study | Country | N | Male (%) | Age (y) | Center | Illness severity scores | Overall risk of bias |
|---|---|---|---|---|---|---|---|
Andrews 2014 [21] | Zambia | 109 | 53.2 | 35.2, 34.8 | S | APACHE II: 17.8, 17.9 | Low |
ARISE 2014 [13] | Australia/New Zealand | 1,588 | 59.8 | 62.7, 63.1 | M | APACHE II: 15.4, 15.8 | Low |
Jing 2010 [8] | China | 317 | 69.3 | 68.9, 67.7 | M | APACHE II: 23.5, 21.8 | Low |
Jones 2010 [22] | USA | 300 | 54.3 | 59.8, 61.6 | M | SAPS II: 44.8, 44.1 | Low |
Lin 2006 [23] | Taiwan | 224 | 58.0 | 67.2, 68.7 | S | APACHE III: 66.5, 64.9 | Low |
ProCESS 2014 [14] | USA | 1,341 | 55.4 | 60, 62 | M | APACHE II: 20.8, 20.7 | Low |
Rivers 2001 [4] | USA | 263 | 50.6 | 67.1, 64.4 | S | APACHE II: 20.4, 21.4 | Low |
Wang 2006 [25] | China | 33 | NA | 33, 36 | S | APACHE II: 28, 27 | Unclear |
Wang 2014 [20] | China | 57 | 70.2 | 52, 56 | S | APACHE II: 19.7, 20.9 | Unclear |
Yu 2013 [24] | China | 50 | 74.0 | 61, 59 | S | APACHE II: 18.2, 17.9 | Unclear |